Target Price | $160.00 |
Price | $123.02 |
Potential |
30.06%
register free of charge
|
Number of Estimates | 23 |
23 Analysts have issued a price target Neurocrine Biosciences, Inc. 2026 .
The average Neurocrine Biosciences, Inc. target price is $160.00.
This is
30.06%
register free of charge
$192.00
56.07%
register free of charge
$115.00
6.52%
register free of charge
|
|
A rating was issued by 27 analysts: 23 Analysts recommend Neurocrine Biosciences, Inc. to buy, 4 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2026 of
30.06%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.36 | 2.69 |
24.81% | 14.03% | |
EBITDA Margin | 25.90% | 18.89% |
17.48% | 27.07% | |
Net Margin | 14.49% | 14.75% |
9.51% | 1.79% |
24 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2025 . The average Neurocrine Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2025. The average Neurocrine Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
20 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2025. The average Neurocrine Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 3.29 | 4.00 |
33.20% | 21.58% | |
P/E | 30.74 | |
EV/Sales | 4.18 |
20 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Neurocrine Biosciences, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Locked
➜
Locked
|
Locked | May 06 2025 |
UBS |
Locked
➜
Locked
|
Locked | May 06 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | May 06 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | May 06 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | May 06 2025 |
BMO Capital |
Locked
➜
Locked
|
Locked | May 06 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 06 2025 |
Analyst Rating | Date |
---|---|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 06 2025 |
Locked
UBS:
Locked
➜
Locked
|
May 06 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
May 06 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
May 06 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
May 06 2025 |
Locked
BMO Capital:
Locked
➜
Locked
|
May 06 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.